Hepatic enhancement and signal intensity analysis on magnetic resonance imaging as prognostic biomarkers in advanced chronic liver disease

Table 10 Receiver operating characteristic curve analysis results for the diagnostic performance of hepatic enhancement, Functional Liver Imaging Score, and clinical scores in predicting mortality¹

Marker	AUC (95%CI)	Youden cut-off	Se	Sp	PPV	NPV	Δ HE vs FLIS (q)	Δ HE vs MELD 3.0 (q)	Δ HE vs ALBI (q)
FLIS	0.81 (0.69-0.93)	4.5	0.92	0.64	0.28	0.98	-	-	-
MELD 3.0	0.79 (0.64-0.94)	15.5	0.77	0.75	0.31	0.96	-	-	-
ALBI	0.82 (0.69-0.95)	-1.4	0.69	0.85	0.41	0.95	-	-	-
HE segment VI	0.74 (0.57-0.91)	75	0.85	0.74	0.32	0.97	-0.07 (0.293)	-0.05 (0.369)	-0.08 (0.220)
HE segment VIII	0.64 (0.46-0.82)	75	0.62	0.74	0.26	0.93	-0.18 (0.025)	-0.15 (0.082)	-0.18 (0.081)
HE segment III	0.71 (0.56-0.87)	87.5	0.77	0.69	0.28	0.95	-0.09 (0.188)	-0.08 (0.267)	-0.11 (0.220)
HE caudate lobe	0.71 (0.55-0.87)	82.5	0.77	0.69	0.27	0.95	-0.09 (0.140)	-0.08 (0.220)	-0.11 (0.170)
HE global	0.71 (0.54-0.88)	86.3	0.85	0.62	0.25	0.96	-0.17 (0.140)	-0.08 (0.220)	-0.11 (0.170)

¹q: P-values adjusted using false discovery rate via the Benjamini-Hochberg test. False discovery rate-significant at q ≤ 0.05.

Δ: Area under the curve difference; ALBI: Albumin-bilirubin score; AUC: Area under the curve; CI: Confidence interval; FLIS: Functional Liver Imaging Score; HE: Hepatic enhancement; MELD 3.0: Model for End-Stage Liver Disease 3.0; NPV: Negative predictive value; PPV: Positive predictive value; Se: Sensitivity; Sp: Specificity.